OpenPrescribing December 2018 Newsletter

New “do not prescribe” measures on OpenPrescribing.net At OpenPrescribing we pride ourselves on developing our tools in response to the needs of our users. Last week NHS England announced a new “Do Not Prescribe” list for consultation. Within an hour we made graphs showing every GP practice’s prescribing of these items. You can drill down to CCG level, and then practice level. We hope that this data will be useful for clinicians and CCG pharmacists to identify where there is most room for improvement, or change.

Read more about OpenPrescribing December 2018 Newsletter

Price Concessions Calculator — A New Feature on OpenPrescribing

This week we launched a new feature on OpenPrescribing, an NHS Price Concession calculator. We show the cost impact of price concessions for the whole of England here and the calculator appears on every single practice and CCG dashboard so you can work out the impact locally. What are price concessions and what are the broader issues? Price concessions are a short term agreement by the NHS to pay more than the already agreed price for a generic medicine because pharmacists are unable to obtain the generic at its usual price.

Read more about Price Concessions Calculator — A New Feature on OpenPrescribing

New measures for latest "Do Not Prescribe" list under consultation

Earlier this week NHS England announced a new “Do Not Prescribe” list for consultation. Within an hour we made graphs showing every GP practice’s prescribing of these items. You can drill down to CCG level, and then practice level. We hope that this data will be useful for clinicians and CCG pharmacists to identify where there is most room for improvement, or change. Or, to drive discussion about agreement on the guidance.

Read more about New measures for latest "Do Not Prescribe" list under consultation

Limitations of NHS England prescribing data

The data that drives OpenPrescribing is described briefly in our FAQ. It is supplied by NHSBSA and NHS Digital, and a few other sources. Over the years we have come to understand the limitations of this data. We’re sharing them here, so researchers can take them into account when carrying out analyses. When using Practice Level Prescribing Data, bear in mind: The data relates to primary care prescribing only. Secondary care prescribing is not included.

Read more about Limitations of NHS England prescribing data

OpenPrescribing October 2018 Newsletter

All England Dashboard - A New Feature on OpenPrescribing.net At OpenPrescribing we pride ourselves on developing our tools in response to the needs of our users. OpenPrescribing is being increasingly used at national organisations and we have had many requests for an All England dashboard. This month we launched the first version of the All England dashboard and blogged about it here. Phenytoin Supply Disruption Alert At the Bennett Institute we get many emails about how people are using OpenPrescribing and this month we blogged about how OpenPrescribing can be helpful when medicines are in short supply.

Read more about OpenPrescribing October 2018 Newsletter

Phenytoin Supply Disruption Alert

Drug supply issues are an interesting use-case for OpenPrescribing. Here we will talk about a recent example. What is the problem? Last week the Department of Health and Social Care issued a “Supply Disruption Alert” for Epanutin (phenytoin) 30mg/5ml oral suspension: Pfizer, the manufacturer, will be out of stock of this product from the week commencing 29th October (today) until early December 2018. This means people currently taking Epanutin (phenytoin) 30mg/5ml oral suspension may need to be prescribed a different product.

Read more about Phenytoin Supply Disruption Alert

All England Dashboard - A New Feature on OpenPrescribing.net

This week we have launched a new page on OpenPrescribing.net, the All England dashboard, that allows anyone to see the quality of prescribing at a national level. For the first time we have aggregated all the savings from all our measures in one place. For the month of August these numbers are quite staggering: £13,190,000 - could potentially have been saved if CCGs used our innovative price-per-unit tool (you can read our methods paper here).

Read more about All England Dashboard - A New Feature on OpenPrescribing.net

IQWiG Response to the EU TrialsTracker

The EU TrialsTracker, which provides the results reporting status of every trial on the EU Clinical Trials Registry, launched last week alongside a paper in the BMJ. We already shared some of the media coverage from the launch of the tracker and comments from Norman Lamb MP, Chair of the House of Commons Science and Technology Committee and Fergus Sweeney, Head of Inspections, Human Medicines Pharmacovigilance and Committees at EMA.

Read more about IQWiG Response to the EU TrialsTracker

The EU TrialsTracker is Live!

Earlier this year we launched our FDAAA TrialsTracker, providing a live look at whether individual sponsors and trialists are meeting their responsibility to report the results of clinical trials on ClinicalTrials.gov. Now we have launched the EU TrialsTracker. This new tracker shows the results status for every trial on the EU Clinical Trials Registry (EUCTR). We are launching the tracker alongside a paper in the BMJ providing a detailed overview of our methods, an analysis of the factors associated with non-reporting and a discussion of the data issues that make assessing compliance difficult on EUCTR.

Read more about The EU TrialsTracker is Live!